OPKO Health to Host Analyst & Investor Day in New York City on June 15

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE:OPK) (« OPKO » or the « Company ») announces
that it will host an Analyst & Investor Day on Wednesday, June 15, 2016
beginning at 4:30 p.m. local time in New York City. Phillip Frost, M.D.,
Chairman and Chief Executive Officer of OPKO Health, will host the event
along with other key members of OPKO Health senior management. The
meeting will focus on OPKO Health’s diversified business units and will
provide an update on continued progress in its research and development
and commercial programs. Expert medical leaders in the fields of
prostate cancer, renal disease and endocrinology will be featured
speakers at the meeting.

The presentations and Q&A will be webcast live beginning at 5:00 p.m.
Eastern time. The live and archived webcast will be available on the
Investor Relations section of OPKO Health’s corporate website at www.opko.com.

About OPKO Health, Inc.

OPKO Health, Inc. is a diversified healthcare company that seeks to
establish industry-leading positions in large, rapidly growing markets.
Our diagnostics business includes Bio-Reference Laboratories, the
nation’s third-largest clinical laboratory with a core genetic testing
business and a 420-person sales force to drive growth and leverage new
products, including the 4Kscore® prostate cancer test and the Claros®1
in-office immunoassay platform. Our pharmaceutical business features
Rayaldee™, a treatment for secondary hyperparathyroidism (SHPT) in stage
3-4 chronic kidney disease (CKD) patients with vitamin D insufficiency
(pending FDA approval) and VARUBI™ for chemotherapy-induced nausea and
vomiting (oral formulation launched by partner Tesaro, IV formulation
(PDUFA January 2017)). Our biologics business includes hGH-CTP, a
once-weekly human growth hormone injection (in Phase 3 and partnered
with Pfizer), and a long-acting Factor VIIa drug for hemophilia
(entering Phase 2a). We also have production and distribution assets
worldwide, multiple strategic investments and an active business
development strategy. More information is available at www.opko.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160614006381/en/